1. Nurse-led pre-test counseling for Alzheimer's disease biomarker testing: Knowledge and skills required to meet the needs of patients and families.
- Author
-
Greer O, Cheng R, Tamres LK, Mattos M, Morris JL, Knox ML, and Lingler JH
- Subjects
- Humans, Nurse's Role, Positron-Emission Tomography methods, Counseling, Biomarkers, Alzheimer Disease diagnosis, Cognitive Dysfunction psychology
- Abstract
Introduction: Biomarker testing for Alzheimer's disease and related disorders (ADRD) brings new opportunities for nurses to foster shared decision-making by leading pre-test counseling (PTC) for patients and families., Methods: Audio-recordings of 18 nurse-led PTC sessions were analyzed to characterize questions posed by patient and family members dyads considering whether to pursue amyloid positron emission tomography., Results: Sessions lasted 20 to 75 minutes and generated rich discussion of the purpose and potential implications of amyloid imaging. Dyads posed questions regarding: basic neuroanatomy; the spectrum of normal cognitive aging to dementia; clinical phenotypes and pathological hallmarks of ADRD; secondary prevention of ADRD; and advance planning. In response, PTC facilitators provided disease-specific education, clarification of overt misconceptions, caregiver support, and emotion de-escalation., Conclusion: Nurses conducting PTC for AD biomarker testing should be equipped to answer questions about topics both directly and indirectly related to testing, and also provide emotional support., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The corresponding author, Dr. Lingler, has provided consultation to Genentech and Biogen, and received research support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly. None of the other co-authors have financial or personal conflicts of interest to declare at this time., (Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF